{
}
Lyell Immunopharma is acquiring cell therapy startup ImmPact Bio for $30 million in cash and 37.5 million shares, with potential additional shares based on milestones. The company is streamlining its research focus on differentiated cellular immunotherapies for cancer, including the promising IMPT-314 therapy for blood cancers, while halting less successful projects. Following challenges since its IPO, Lyell aims for a turnaround with a financial runway extending into 2027.
Lynn Seely
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
lyell immunopharma acquires immPact bio to refocus on cancer therapies
23:54 24.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Retail and Consumer Goods
Supply Chain Management
Startups & Entrepreneurship
Global Trade Developments
Workplace Trends
Government Economic Policies
Stock Market Updates
Industry Mergers & Acquisitions
CEO Changes
Venture Capital Investments
Finance Mergers & Acquisitions
Fintech Startups
Cryptocurrency & Blockchain Regulations
Energy Sector Developments
Emerging Startups
Financial Scams and Security
Cryptocurrency Trends
Funding Rounds & Investments
Countries:
Companies:
Apple Inc.
Google Inc.
Alphabet Inc.
NVIDIA Corporation
Tesla, Inc.
Microsoft Corporation
Amazon.com, Inc.
Delhivery Limited
Ecom Express Ltd.
Foxconn Technology Co., Ltd.
Samsung SDI Co., Ltd.
SWIGGY LIMITED
Netflix, Inc.
Airbnb, Inc.
Adobe Inc.
GEELY AUTO
TENCENT
CarTrade Tech Limited
CapitaLand Investment Ltd
HMC Capital Ltd
Currencies:
United States Dollar
Chinese Yuan
Euro
Indian Rupee
Japanese Yen
South Korean Won
Vietnamese Đồng
Indonesian Rupiah
Algerian Dinar
Australian Dollar
Egyptian Pound
Saudi Riyal
Swiss Franc
British Pound Sterling
Russian Ruble
People: